Characteristics of patients who discontinued ibrutinib
| Characteristic . | Category . | Overall, N = 33 . |
|---|---|---|
| Age, years | Median (range) | 61 (36-83) |
| White blood cell, K/μL | Median (range) | 24 (2-323) |
| Rai stage, 3-4 | Advanced | 76% |
| CD38, >30% | High | 52% |
| Zap-70 positive | By immunohistochemistry | 70% |
| β2 M, mg/L | ≥4 mg/L | 61% |
| IGHV mutation | Unmutated | 94% |
| Fluorescence in situ hybridization category | del17p/del11q/others | 58%/18%/24% |
| Karyotype | Complex | 54% |
| Number of prior therapies | ≥3 | 45% |
| Median number of prior therapies | Median (range) | 2 (0-7) |
| Median time from diagnosis to ibrutinib, months | Median (range) | 59 (8-150) |
| Characteristic . | Category . | Overall, N = 33 . |
|---|---|---|
| Age, years | Median (range) | 61 (36-83) |
| White blood cell, K/μL | Median (range) | 24 (2-323) |
| Rai stage, 3-4 | Advanced | 76% |
| CD38, >30% | High | 52% |
| Zap-70 positive | By immunohistochemistry | 70% |
| β2 M, mg/L | ≥4 mg/L | 61% |
| IGHV mutation | Unmutated | 94% |
| Fluorescence in situ hybridization category | del17p/del11q/others | 58%/18%/24% |
| Karyotype | Complex | 54% |
| Number of prior therapies | ≥3 | 45% |
| Median number of prior therapies | Median (range) | 2 (0-7) |
| Median time from diagnosis to ibrutinib, months | Median (range) | 59 (8-150) |